Pharmacia & Upjohn

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995.[1] Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

Pharmacia & Upjohn
TypePublic
IndustryPharmaceutical
FateAcquired by Pfizer
FoundedMerger of Pharmacia AB & The Upjohn Company

History

Amersham

In 1997, the biotechnology division of the company Pharmacia Biotech merged with Amersham Life Science with the new merged entity being known as Amersham Pharmacia Biotech.[2][3] In 2001, the company was renamed Amersham Biotech.[4] In 2002, Pharmacia sold its share of the company to Amersham plc.[5][6] In 2004, Amersham Biosciences was acquired by GE Healthcare.[7]

In 1998, the nutrition division of the company was sold to Fresenius.[8]

Monsanto

Monsanto acquired the pharmaceutical company G. D. Searle & Company in 1985.[9] In 1998, Searle and the Monsanto Pharma Sector partnered with Pfizer to develop and promote celecoxib, an anti-inflammatory drug used to treat arthritis.[10][11] Branded as Celebrex, celecoxib was approved by the FDA in 1998.[12] In December 1999, Pharmacia & Upjohn merged with the American biotechnology and medical company, Monsanto and renamed itself Pharmacia.[13] The company retained Monsanto's pharmaceutical division - then known as Searle - and spun off the remaining interests as the "new Monsanto".[14][15] The newly merged pharmaceutical entity changed its name to Pharmacia Corp.[16]

Pfizer

In July 2002, Pharmacia Corp. and Pfizer announced an agreement that Pfizer would purchase Pharmacia; control of celecoxib was often mentioned as a key reason for Pfizer's acquisition of Pharmacia.[17] The deal was finalized in April 2003.[18]

Later developments
  • The remnant of the Stockholm-based part of Pharmacia was partly spun off to Biovitrum in 2001,[19][20] which sold off its plasma products division to Octapharma in 2002.[21]
  • In 2004, the allergy-diagnostic division of Pharmacia was sold off as Pharmacia Diagnostics.[22] Later in 2004, the Uppsala-based ophthalmology division was sold to Advanced Medical Optics.[23]
  • In April 2006, Pharmacia Diagnostics changed its name to Phadia, which ended the use of the Pharmacia trademark.[24] In September, Phadia was acquired by PPM Capital.[24] In April 2006, Indian company Kemwell acquired Pfizer's Uppsala manufacturing plant that used to be under Pharmacia.[25] The company's facilities in Strängnäs Sweden are currently being expanded for the production of Genotropin, a growth hormone.[26]

Overview

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Pharmacia Corp.
Acquired by Pfizer, 2002

Pharmacia & Upjohn
Pharmacia
(Merged 1995)
Kabi Pharmacia
Pharmacia Biotech
 

LKB-produkter AB
(Acq 1968)

 
 

PL Laboratories

 
 
 

Kabi Vitrum
(Acq 1990)

 
 
 

Farmitalia
(Acq 1993)

 
 
 

Upjohn
(Merged 1995)

 
 
Monsanto
 

Monsanto

 
 

G. D. Searle & Company
(Acq 1985)

 
 
 

References
  1. "Upjohn Company". 7 May 2006. Archived from the original on 2006-05-07.
  2. Newman, Cathy (1997-05-31). "Amersham close to life sciences merger". The Independent. Retrieved 2020-11-16.
  3. Stephen, Moore (1997-06-11). "Amersham Merges Division With Pharmacia & Upjohn". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-11-16.
  4. Basar, Shanny (12 March 2002). "Morgan Stanley and Hoare Govett sell £350m Amersham sale". Financial News London. Retrieved 2020-11-16.
  5. "Pharmacia Corp selling stake in Amersham Biosciences for $1 billion -". The Pharma Letter. 18 March 2002. Retrieved 2020-11-16.
  6. "Amersham buys out bioscience ally". the Guardian. 2002-03-13. Retrieved 2020-11-16.
  7. Rovito, Rich (8 April 2004). "GE completes acquisition of Amersham, restructures GE Healthcare". Milwaukee Business Journal.
  8. "INTERNATIONAL BRIEFS; Fresenius of Germany Buying Pharmacia Unit (Published 1998)". The New York Times. 1998-06-09. ISSN 0362-4331. Retrieved 2020-11-16.
  9. Greenhouse, Steven (1985-07-19). "MONSANTO TO ACQUIRE G. D. SEARLE (Published 1985)". The New York Times. ISSN 0362-4331. Retrieved 2020-11-16.
  10. "Monsanto's Searle unit developing arthritis drug with Pfizer". St. Louis Business Journal. 18 February 1998.
  11. Langreth, Robert (1998-02-19). "Pfizer to Help Searle Develop, Market Arthritis Drug in Race With Merck, J&J". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-11-16.
  12. "Fast Facts on Bextra and Celebrex". ABC News. 6 January 2006. Retrieved 2020-11-16.
  13. Stein, George; Chase; Brett (1999-12-20). "Pharmacia & Upjohn, Monsanto to Merge in $26.5-Billion Deal". Los Angeles Times. Retrieved 2020-11-16.
  14. "Monsanto Raises $700 Million in IPO". Los Angeles Times. October 18, 2000.
  15. "Monsanto and Pharmacia to Join, Creating a Pharmaceutical Giant", New York Times, December 20, 1999, retrieved 28 December 2015
  16. "Drug cos. to call new firm 'Pharmacia'". CNN Money. 27 January 2000. Retrieved 2020-11-16.
  17. Sorkin, Andrew (15 July 2002). New York Times Pfizer Said To Buy Large Drug Rival In $60 Billion Deal https://www.nytimes.com/2002/07/15/business/pfizer-said-to-buy-large-drug-rival-in-60-billion-deal.html Pfizer Said To Buy Large Drug Rival In $60 Billion Deal Check |url= value (help). Missing or empty |title= (help)
  18. "It's official: Pfizer buys Pharmacia". 16 April 2003.
  19. "Pharmacia Spins Off Metabolic Disease Business Into Biovitrum + | Bioworld". BioWorld. 8 August 2001. Retrieved 2020-11-16.
  20. "COMPANY NEWS; PHARMACIA TO CREATE SEPARATE BIOTECHNOLOGY COMPANY (Published 2001)". The New York Times. 2001-01-13. ISSN 0362-4331. Retrieved 2020-11-16.
  21. Sheridan, Cormac (3 July 2002). "Biovitrum Sells Off Plasma Business To Swiss Company + | Bioworld". BioWorld. Retrieved 2020-11-16.
  22. "Pfizer to Sell Diagnostics Unit To Two Firms for $575 Million". Wall Street Journal. 2004-01-20. ISSN 0099-9660. Retrieved 2020-11-16.
  23. "Pfizer sells surgical ophalmics business for $450M - Pharmaceutical in". The Pharma Letter. 25 April 2004. Retrieved 2020-11-16.
  24. Parkinson, Gary (2006-09-18). "Phadia sale to deepen concerns over private equity debt". The Independent. Retrieved 2020-11-16.
  25. "Kemwell acquires Pfizer facility". New Europe. 2006-04-02. Retrieved 2020-11-16.
  26. Macdonald, Gareth (25 August 2009). "Pfizer inaugurates new $214m Swedish biotech plant". BioPharma Reporter. Retrieved 2020-11-16.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.